作者
Hossein-Ardeschir Ghofrani, Gérald Simonneau, Andrea M D'Armini, Peter Fedullo, Luke S Howard, Xavier Jaïs, David P Jenkins, Zhi-Cheng Jing, Michael M Madani, Nicolas Martin, Eckhard Mayer, Kelly Papadakis, Dominik Richard, Nick H Kim, Irene Lang, Christian Kähler, Marion Delcroix, Zoheir Bshouty, Pablo Sepulveda Varela, Yuanhua Yang, Jinming Liu, Gangcheng Zhang, Nuofu Zhang, Yuhong Mi, Xianyang Zhu, Pavel Jansa, Grégoire Prévot, Hélène Bouvaist, Olivier Sanchez, Friedrich Grimminger, Matthias Held, Heinrike Wilkens, Stephan Rosenkranz, Ekkehard Grünig, Kristóf Karlócai, András Temesvári, Istvan Edes, Sigita Aidietienė, Skaidrius Miliauskas, Tomas Rene Pulido Zamudio, Carlos Jerjes Sanchez, Anton Vonk Noordegraaf, Jerzy Lewczuk, Piotr Podolec, Jarosław Kasprzak, Tatiana Mularek-Kubzdela, Ryszard Grzywna, Keertan Dheda, Olga Moiseeva, Alexander Chernyavskiy, Vladimir Shipulin, Olga Barbarash, Tamila Martynyuk, Hyung-Kwan Kim, Jun-Bean Park, Jae Seung Lee, Rudolf Speich, Silvia Ulrich, John-David Aubert, Arintaya Phrommintikul, Nattapong Jaimchariyatam, Suree Sompradeekul, Zeynep Pinar Onen, Gulfer Okumus, Lyubomyr Solovey, Volodymyr Gavrysyuk, Luke Howard, Joanna Pepke-Zaba, Robin Condliffe, John McConnell, Kim Kerr, Lan Hieu Nguyen, Nguyen Vinh Pham
发表日期
2024/4/1
期刊
The Lancet Respiratory Medicine
卷号
12
期号
4
页码范围
e21-e30
出版商
Elsevier
简介
Background
Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar.
Methods
The phase 2, double-blind, randomised, placebo-controlled MERIT-1 trial assessed macitentan in 80 patients with CTEPH adjudicated as inoperable. Patients identified as WHO functional class II–IV with a pulmonary vascular resistance (PVR) of at least 400 dyn·s/cm5 and a walk distance of 150–450 m in 6 min were randomly assigned (1:1), via an interactive voice/web response system, to receive oral macitentan (10 mg once a day) or placebo. Treatment with phosphodiesterase type-5 inhibitors and oral or inhaled prostanoids was permitted for WHO functional class III/IV patients. The primary endpoint was resting PVR at week 16, expressed as percentage of PVR measured at …
学术搜索中的文章
HA Ghofrani, G Simonneau, AM D'Armini, P Fedullo… - The Lancet Respiratory Medicine, 2024